Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch
  

Ibc Pharmaceuticals Inc patents

Recent patent applications related to Ibc Pharmaceuticals Inc. Ibc Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Ibc Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Ibc Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Ibc Pharmaceuticals Inc-related inventors




Date Ibc Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
06/15/17Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
05/04/17Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
03/30/17Dock-and-lock (dnl) complexes for therapeutic and diagnostic use
03/02/17Tetrameric cytokines with improved biological activity
01/26/17Combination therapy for inducing immune response to disease
01/26/17T-cell redirecting bispecific antibodies for treatment of disease
12/29/16Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
12/15/16Dock-and-lock (dnl) vaccines for cancer therapy
12/15/16Pegylation by the dock and lock (dnl) technique
11/24/16Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
10/27/16Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
09/15/16Disease therapy by inducing immune response to trop-2 expressing cells
09/08/16Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
08/25/16Combination therapy with anti-cd74 and anti-cd20 antibodies provides enhanced toxicity to b-cell diseases
06/23/16T-cell redirecting bispecific antibodies for treatment of disease
06/23/16T-cell redirecting bispecific antibodies for treatment of disease
05/12/16Interferon lambda-antibody complexes
03/31/16Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
12/31/15Methods and compositions for generating bioactive assemblies of increased complexity and uses
08/20/15Combination therapy for inducing immune response to disease
05/14/15Disease therapy by inducing immune response to trop-2 expressing cells
05/07/15Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
02/26/15Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
02/19/15Stably tethered structures of defined compositions with multiple functions or binding specificities
02/05/15Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
01/22/15Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
01/22/15Dock-and-lock (dnl) complexes for therapeutic and diagnostic use
01/22/15Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
01/08/15Methods and compositions for generating bioactive assemblies of increased complexity and uses
06/12/14Tetrameric cytokines with improved biological activity
04/10/14Combination therapy for inducing immune response to disease
02/20/14T-cell redirecting bispecific antibodies for treatment of disease
02/13/14Novel strategies for improved cancer vaccines
12/05/13Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
08/22/13Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
07/11/13Pegylation by the dock and lock (dnl) technique
06/27/13Methods and compositions for generating bioactive assemblies of increased complexity and uses
05/30/13Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
05/02/13Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
04/18/13Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
03/28/13Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
11/01/12Multivalent immunoglobulin-based bioactive assemblies
09/20/12Design and construction of novel multivalent antibodies
09/06/12Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
08/02/12Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
04/19/12Stem cell targeting with dock-and-lock (dnl) complexes
04/05/12Dock-and-lock (dnl) constructs for human immunodeficiency virus (hiv) therapy
01/12/12Tetrameric cytokines with improved biological activity
12/29/11Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
12/08/11Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
09/29/11Pegylation by the dock and lock (dnl) technique
08/11/11Methods and compositions for generating bioactive assemblies of increased complexity and uses
08/04/11Dock-and-lock (dnl) vaccines for cancer therapy
06/30/11Dock-and-lock (dnl) complexes for therapeutic and diagnostic use
06/16/11Stably tethered structures of defined compositions with multiple functions or binding specificities
05/26/11Dock-and-lock (dnl) complexes for delivery of interference rna
05/12/11Multivalent immunoglobulin-based bioactive assemblies
01/27/11Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
01/13/11Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
10/14/10Pegylation by the dock and lock (dnl) technique
09/02/10Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
07/29/10Tetrameric cytokines with improved biological activity
03/18/10Dock-and-lock (dnl) vaccines for cancer therapy
10/29/09Multivalent immunoglobulin-based bioactive assemblies
08/13/09Methods and compositions for generating bioactive assemblies of increased complexity and uses
Patent Packs
08/13/09Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
07/30/09Stably tethered structures of defined compositions with multiple functions or binding specificities
03/05/09Pegylation by the dock and lock (dnl) technique







ARCHIVE: New 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ibc Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ibc Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';